TERT and neoplasm: As expected, the frequency of TERT Th1 responders against the UCP peptide pool was greater in localized vs metastatic NSCLC (45% vs. 24%, respectively) [110], pointing to a link between functional anti-TERT CD4 T cell immunity in peripheral blood and tumor progression.